Molecular Interactions between Kaempferol and Apolipoprotein A-I (APOA1) of Rattus Norvegicus of Using Drug Docking
R.Sathya
Department of Biochemistry, K.M.G. College of Arts and Science, Gudiyatham, 635803, India.
Thirumagal .J *
Department of Biochemistry, K.M.G. College of Arts and Science, Gudiyatham, 635803, India.
*Author to whom correspondence should be addressed.
Abstract
Nowadays, pharmacological research investigations are essential to the development of new medication prospects. We have created high-resolution synteny and rearrangement breakpoint maps across the human, mouse, and rat genomes using paired-end sequences from bacterial artificial chromosomes. Apolipoprotein A-I (APOA1) is often associated with a markedly elevated risk of atherosclerosis and cardiovascular disease. Several studies in the field of clinico-genetics have confirmed this fact. In this work, we employ 3D Insilico drug docking techniques to simulate kaempferol interactions with the potential mutant target protein Apolipoprotein A-I (APOA1). Kaempferol is one of the primary phytochemicals present in Hibiscus rosa-sinensis. Numerous pharmacological effects of Hibiscus rosa-sinensis have been shown to be effective in treating a wide spectrum of human ailments. We look into the connection between APOA1 and kaempferol. In post-docking tests, advanced 3D molecular visualization capabilities were utilized. Kaempferol directly reduces amino acid mutational sites, as indicated by the docking study results. The molecular 3D H-bond interaction between APOA1 and Kaempferol is illustrated using concepts of molecular dynamics techniques based on 3D views. Docking studies play a key role in pharmaceutical researches for the production of novel drug candidates. Thus, investigations on Rattus norvegicus with kaempferol plays a significant role in the pharmacological industry in designing innovative medication candidates. Lastly, we conclude that kaempferol is protective against cardiovascular diseases associated with atherosclerosis.
Keywords: Apolipoprotein A-I (APOA1), kaempferol, drug docking, In silico